0
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      In Vivo Evaluation of the Acute Systemic Toxicity of (1S,2E,4R,6R,7E,11E)-Cembratriene-4,6-diol (4R) in Sprague Dawley Rats

      research-article

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          The tobacco cembranoid (1S,2E,4R,6R,7E,11E)-2,7,11-cembratriene-4,6-diol (4R) interacts with nicotinic acetylcholine receptors, which results in neuroprotection against organophosphate toxicity, brain ischemia, and Parkinson’s disease. The present study is a continuation of our previous research in which we applied a single dose of 4R 1 h before or 24 h after exposure to diisopropylfluorophosphate (DFP) (analog of the nerve agent sarin). The 4R dose robustly decreased neuroinflammation and neuronal death at both timepoints. Here, we investigated the toxicity of a single dose of 4R in male and female Sprague Dawley (SD) rats after a subcutaneous (s.c.) injection of 6, 24, or 98 mg/kg. Body weight was not affected by 4R during the 7-day observation period. No histopathologic changes in the organs were attributed to 4R. Minor hematological and blood composition variations were detected on Day 3 in the mid- and the high-dose males, but these were resolved by Day 8. At the area of the s.c. injection site, alopecia and dry skin were detected in both the 4R-treated males and females and in the female controls.

          Related collections

          Most cited references34

          • Record: found
          • Abstract: found
          • Article: not found

          Poly(ethylene glycol) in drug delivery: pros and cons as well as potential alternatives.

          Poly(ethylene glycol) (PEG) is the most used polymer and also the gold standard for stealth polymers in the emerging field of polymer-based drug delivery. The properties that account for the overwhelming use of PEG in biomedical applications are outlined in this Review. The first approved PEGylated products have already been on the market for 20 years. A vast amount of clinical experience has since been gained with this polymer--not only benefits, but possible side effects and complications have also been found. The areas that might need consideration and more intensive and careful examination can be divided into the following categories: hypersensitivity, unexpected changes in pharmacokinetic behavior, toxic side products, and an antagonism arising from the easy degradation of the polymer under mechanical stress as a result of its ether structure and its non-biodegradability, as well as the resulting possible accumulation in the body. These possible side effects will be discussed in this Review and alternative polymers will be evaluated.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: found
            Is Open Access

            Subcutaneous Administration of Biotherapeutics: An Overview of Current Challenges and Opportunities

            Subcutaneous delivery of biotherapeutics has become a valuable alternative to intravenous administration across many disease areas. Although the pharmacokinetic profiles of subcutaneous and intravenous formulations differ, subcutaneous administration has proven effective, safe, well-tolerated, generally preferred by patients and healthcare providers and to result in reduced drug delivery-related healthcare costs and resource use. The aim of this article is to discuss the differences between subcutaneous and intravenous dosing from both health-economic and scientific perspectives. The article covers different indications, treatment settings, administration volumes, and injection devices. We focus on biotherapeutics in rheumatoid arthritis (RA), immunoglobulin-replacement therapy in primary immunodeficiency (PI), beta interferons in multiple sclerosis (MS), and monoclonal antibodies (mAbs) in oncology. While most subcutaneous biotherapeutics in RA, PI, and MS are self-administered at home, mAbs for oncology are still only approved for administration in a healthcare setting. Beside concerns around the safety of biotherapeutics in oncology, a key challenge for self-administration in this area is that doses and dosing volumes can be comparatively large; however, this difficulty has recently been overcome to some extent by the development of high-concentration solutions, the use of infusion pumps, and the coadministration of the dispersion enhancer hyaluronidase. Furthermore, given the increasing number of biotherapeutics being considered for combination therapy and the high dosing complexity associated with these, especially when administered intravenously, subcutaneous delivery of fixed-dose combinations might be an alternative that will diminish these burdens on healthcare systems.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Mean platelet volume: a link between thrombosis and inflammation?

              Platelet activation is a link in the pathophysiology of diseases prone to thrombosis and inflammation. Numerous platelet markers, including mean platelet volume (MPV), have been investigated in connection with both thrombosis and inflammation. This review considers MPV as a prognostic and therapeutic marker as well as the factors influencing its measurement. Established cardiovascular risk factors, such as smoking, hypertension, dyslipidemia, and diabetes, can influence MPV, depending on confounding factors. Low-grade inflammation is one such factor. Evidence, particularly derived from prospective studies and a meta-analysis, suggest a correlation between an increase in MPV and the risk of thrombosis. High MPV associates with a variety of established risk factors, cardio- and cerebrovascular disorders, and low-grade inflammatory conditions prone to arterial and venous thromboses. High-grade inflammatory diseases, such as active rheumatoid arthritis or attacks of familial Mediterranean fever, present with low levels of MPV, which reverse in the course of anti-inflammatory therapy. Lifestyle modification, antihypertensive, lipid lowering and diet therapies can also affect MPV values, but these effects need to be investigated in large prospective studies with thrombotic endpoints.
                Bookmark

                Author and article information

                Journal
                9918419282306676
                51764
                Nutraceuticals (Basel)
                Nutraceuticals (Basel)
                Nutraceuticals
                1661-3821
                30 June 2022
                June 2022
                09 April 2022
                18 July 2022
                : 2
                : 2
                : 60-70
                Affiliations
                [1 ]Department of Neuroscience, Medical of School, Universidad Central del Caribe, Bayamón, PR 00956, USA
                [2 ]Department of Biology, West Chester University, 750 S Church St., West Chester, PA 19383, USA
                [3 ]Neuroprotection for Life, Carmel, IN 46032, USA
                Author notes

                Author Contributions: Conceptualization, P.A.F., N.S., O.R.P. and V.A.E.; methodology, P.A.F. and N.S.; validation, N.S.; formal analysis, P.A.F., N.S. and O.R.P.; investigation, P.A.F., N.S., O.R.P. and V.A.E.; data curation, N.S. and O.R.P.; writing—original draft preparation, P.A.F., N.S. and O.R.P.; writing—review and editing, Y.F.-A.; visualization, N.S.; supervision, N.S. and P.A.F.; project administration, P.A.F. and N.S.; funding acquisition, P.A.F. and N.S. All authors have read and agreed to the published version of the manuscript.

                [* ]Correspondence: nadezhda.sabeva@ 123456gmail.com ; Tel.: +1-787-798-3001 (ext. 2169)
                Author information
                http://orcid.org/0000-0002-7714-4884
                Article
                NIHMS1798958
                10.3390/nutraceuticals2020005
                9291268
                35855209
                f1183773-1d63-436f-9851-914050a08d70

                This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license ( https://creativecommons.org/licenses/by/4.0/).

                History
                Categories
                Article

                cembranoids,subacute toxicity,nicotiana tabacum
                cembranoids, subacute toxicity, nicotiana tabacum

                Comments

                Comment on this article